Latest Updates
8/23/2019 - Management of NASH
9/4/2018 - Other Viruses
9/4/2018 - Other Viruses
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
8/17/2018 - HCV Management in Special Populations
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/24/2018 - Management of HCV Infection
7/10/2018 - Hepatitis Virology/Immunology
7/10/2018 - Hepatitis Virology/Immunology
7/10/2018 - Hepatitis Virology/Immunology
7/10/2018 - Hepatitis Virology/Immunology
7/2/2018 - HBV Epidemiology
7/2/2018 - HBV Epidemiology
7/2/2018 - HBV Epidemiology
6/4/2018
-
HBV in Special Populations
- New AASLD guidance on diagnosis and management of key HBV coinfections (ie, HIV, HCV, or HDV)
- Updated discussion of HBV management before, during, and after pregnancy
- New AASLD guidance on HBV management in patients at risk for HBV reactivation, including those slated for immunosuppressive or cytotoxic therapy
6/1/2018 - Hepatitis Delta Virus
5/25/2018 - Hepatitis B Management
5/25/2018 - Hepatitis B Management
5/25/2018 - Hepatitis B Management
5/25/2018 - Hepatitis B Management
5/25/2018 - Hepatitis B Management
5/25/2018 - Hepatitis B Management
5/23/2018
-
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
- Updated data on global prevalence of HCV infection
- New data on HCV transmission via organ transplant from seropositive, NAT-negative donors
- Updated IDU prevalence rates and reinfection risk estimates
- Recent studies on HCV sexual transmission highlight risk factors among women sex workers and MSM
- New data on HCV seroprevalence and reinfection risk among incarcerated persons
- Latest risk-based guidance on anti-HCV screening
- HCV testing algorithm for follow-up of individuals testing anti-HCV positive
- Currently available assays for HCV RNA detection and guidance on interpreting assay results
- Recent data on risk factors for and rate of liver biopsy-associated complications
- Updated data on primary HCV infection in the United States
5/17/2018
-
HAV and HEV
- Updated with latest guidance from the CDC and Public Health England on testing for acute HAV and acute HEV infections
- New epidemiologic data on acute HAV outbreaks in the United States and European Union among unvaccinated, high-risk populations
- New epidemiologic data on acute HEV infections among human and animal reservoir populations, including updated risk factors for HEV transmission
- Updated diagnosis information and epidemiologic data on chronic HEV infection in immunosuppressed transplantation patients
- New guidance on HAV vaccinations, including interim guidance in response to ongoing outbreaks in the United States and European Union, from the CDC and Public Health England
5/9/2018
-
Management of HCV Infection
- New guidance on clinical strategies to reduce risk of HCV reinfection among at-risk populations, including persons who inject drugs, HIV-coinfected men who have sex with men, and individuals in correctional settings
- Updated data from phase II C-SCAPE and phase III C-EDGE TE of elbasvir/grazoprevir ± ribavirin in treatment-naive and treatment-experienced patients
- Updated data from phase III ENDURANCE-1 trial of 8- vs 12-week courses of glecaprevir/pibrentasvir in noncirrhotic patients with genotype 1 HCV, including HIV coinfection
- Updated real-world data for ledipasvir/sofosbuvir-containing regimens in patients with genotype 1 HCV
11/21/2017 - Management of HCV Infection
9/28/2017 - Management of HCV Infection
6/28/2017 - Hepatitis B Management
5/25/2017
-
HBV in Special Populations
- New EASL guidance on management of HBV in patients coinfected with HBV and
HIV
- New guidance from AASLD and EASL on the management of HBV reactivation in
HBV/HCV-coinfected patients
- New EASL guidance on the management of HBV in women of childbearing age,
including status of tenofovir AF
- Latest recommendations on monitoring patients at risk of HBV
reactivation
5/25/2017
-
Management of HCV Infection
- Updated AASLD/IDSA guidance on initial HCV treatment now recommends 8-week
ledipasvir/sofosbuvir for treatment-naive nonblack patients with genotype 1 HCV infection, no cirrhosis, no HIV coinfection, and baseline HCV RNA < 6 million IU/mL
- Revised AASLD/IDSA guidance on retreatment of genotype 3 HCV infection
2/24/2017
-
Hepatitis B Management
- New discussion on tenofovir alafenamide fumarate including data on noninferiority to tenofovir disoproxil fumarate
- Combination of peginterferon alfa-2a with tenofovir DF demonstrated a significantly higher rate of HBsAg loss after 48 weeks of treatment vs peginterferon monotherapy, but seroreversion after discontinuation attenuated initial differences
- Adding tenofovir DF to entecavir showed similar rates of HBV DNA < 15 IU/mL compared with tenofovir DF alone in patients with documented entecavir resistance
- New discussion on adding or switching to peginterferon alfa-2a following nucleo(s)tide therapy
- Updated with current guidance from the 2016 Asian-Pacific consensus statement
7/26/2016 - Hepatitis B Management
2/23/2016 - HBV in Special Populations
10/7/2015
-
HAV and HEV
- Updated with new guidance from Public Health England on screening for HEV
- Included updated epidemiologic data on HAV from the CDC
- Included updated epidemiologic data on HEV the National Health and Nutrition Examination Survey
- Updated with guidance from the CDC on use of hepatitis A adult vaccine as postexposure prophylaxis
- Included new data on the long-term efficacy of the HEV 239 vaccine
9/28/2015
-
Other Viruses
- New phase III trials of brincidofovir vs valganciclovir for prevention of CMV in kidney transplant recipients
- New data on a live attenuated varicella vaccine
- New phase III trial of brincidofovir for treatment of adenovirus infection
- New data on pleconaril in neonates with enterovirus sepsis
- New data on a tetravalent dengue vaccine
- Updated information on candidate treatments and vaccines for Ebola
9/9/2015
-
Hepatitis B Management
- Several studies show viral suppression with nucleos(t)ide analogues may reduce but not eliminate risk of HCC, especially in patients with cirrhosis
- Combination tenofovir plus emtricitabine more effective than tenofovir alone in patients with HBeAg-positive disease with high viral load and low ALT
- Data suggest treatment with nucleo(s)tide analogues associated with good renal and bone safety profiles
- Recent data show only 70% HBV treatment adherence, and younger patients more likely to be nonadherent
8/28/2015
-
HBV in Special Populations
- Included new guidance from the American Gastroenterological Association on the prevention and treatment of HBV reactivation in patients receiving immunosuppressive therapy
- Updated with current guidance from the EACS and DHHS on treatment of HBV/HIV coinfected patients
- Updated with new recommendations on the treatment of HBV/HCV coinfection
8/27/2015 - Hepatitis Virology/Immunology
7/24/2015
-
Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
- Updated global epidemiologic data from the CDC
- Data suggesting rate of reinfection among IDUs low after treatment with antiviral therapy
- Interferon-free regimens provide means of treating HCV-related autoimmune conditions with contraindications to interferon
- Study suggesting no association between HCV and diabetes in US population
- New data demonstrating predominant role of host genetic variants in MHC in accelerated liver fibrosis
- Updated to reflect current guidance from EASL
5/19/2015
-
HBV Epidemiology
- Updated to reflect recent epidemiologic data from the 2013 CDC Surveillance for Viral Hepatitis report
- New data showing most cases of HBV in the US and Canada are in patients born outside of North America
- New data from Taiwan and Germany showing HBV prevalence remains high
- Previously vaccinated healthcare workers with low levels of anti-HBs have a rapid and robust response to booster vaccine, a finding that supports the recommendation that booster doses are not required in persons with normal immune systems
- National and international guidelines recommend HBV screening to patients initiating immunosuppressive therapy to prevent reactivation
5/12/2015 - Hepatitis Delta Virus
10/29/2014
-
Hepatitis B Management
- Updated to reflect current guidance from the APASL on the management of hepatitis B
- Updated epidemiologic data from the WHO
- New data demonstrate efficacy of using tenofovir alone in patients with lamivudine resistance
- New discussion of the risk of hepatocellular carcinoma in patients with decompensated cirrhosis receiving treatment for 5 years
- New section summarizing key roles for primary care physicians in the management of patients with HBV infection
9/16/2014
-
HAV and HEV
- Updated with new data suggesting host-specific rather than virus specific factors are responsible for fulminant hepatitis in patients with HEV
- Included new data on ribavirin treatment for solid organ transplant patients with HEV
- Included new data on the prevalence of HEV in patients with HIV awaiting solid organ transplantation
- Included new section with key information for primary care providers
9/3/2014
-
Other Viruses
- Included prevalence data of CMV disease in liver transplant patients
- Included phase 3 study on dengue virus vaccine
- Updated with new AST Infectious Diseases Guidelines on Cytomegalovirus; Epstein-Barr virus; Herpes simplex virus; HHV-6, HHV-7, HHV-8; Varicella zoster virus; Adenovirus; and Human parvovirus B19
- Included a new section with key information for primary care physicians
8/6/2014 - Hepatitis Virology/Immunology
6/23/2014
-
Hepatitis Delta Virus
- New data indicate that HDV RNA levels may be prognostic for the development of cirrhosis and hepatocellular carcinoma
- Long-term follow-up of HBV/HDV-infected patients who responded to treatment with peginterferon demonstrates a high rate of relapse over time
- New section summarizing key roles for primary care physicians in the management of HDV infection
6/18/2014
-
HBV Epidemiology
- The latest global HBV epidemiology data indicate that west sub-Saharan Africa has the highest HBV prevalence
- Incidence of acute HBV continues to decline in the United States
- 30-year follow-up confirms continued reduction in liver-related mortality following introduction of universal HBV immunization in Taiwan
- Updated guidance from the US Preventive Services Task Force now includes recommendations for HBV screening in individuals at high risk for infection
- New data on HBsAg level changes during nucleos(t)ide analogue therapy
- New section summarizing key roles for primary care physicians in the prevention and identification of HBV infection
2/25/2014 - Hepatitis C Virus Epidemiology, Pathogenesis, Diagnosis, and Natural History
Updated to include revised guidelines from the AASLD/IDSA on the following topics:
- Situations where barrier protection during intercourse is recommended to prevent sexual transmission of HCV
- HCV testing recommendations for persons with tattoos received in unregulated settings
- Counseling patients with HCV infection on measures to prevent transmission to others
- Birth cohort and risk-based screening for HCV infection
- Serologic assays for initial detection of HCV infection
- HCV RNA testing
- Strategies for assessing liver disease in patients with HCV infection